Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

A new insight into the formation of osteolytic lesions in multiple myeloma.

Glass DA 2nd, Patel MS, Karsenty G.

N Engl J Med. 2003 Dec 25;349(26):2479-80. No abstract available.

PMID:
14695406
2.

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr.

N Engl J Med. 2003 Dec 25;349(26):2483-94.

3.

DKK1 in multiple myeloma.

Hofbauer LC, Neubauer A, Schoppet M.

N Engl J Med. 2004 Apr 1;350(14):1464-6; author reply 1464-6. No abstract available.

PMID:
15074002
4.

DKK1 in multiple myeloma.

Lu CM.

N Engl J Med. 2004 Apr 1;350(14):1464-6; author reply 1464-6. No abstract available.

PMID:
15074001
5.

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.

Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy JD Jr.

Blood. 2008 Jul 1;112(1):196-207. doi: 10.1182/blood-2008-01-132134. Epub 2008 Feb 27.

6.

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI.

J Bone Miner Res. 2009 Mar;24(3):425-36. doi: 10.1359/jbmr.081104.

7.
8.

Bone lesions in molecular subtypes of multiple myeloma.

Robbiani DF, Chesi M, Bergsagel PL.

N Engl J Med. 2004 Jul 8;351(2):197-8. No abstract available.

9.

Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.

Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, Bonomini S, Sala R, Mangoni M, Rizzoli V.

Cancer Res. 2007 Aug 15;67(16):7665-74.

11.

DKK1 in multiple myeloma.

Meyer MA.

N Engl J Med. 2004 Apr 1;350(14):1464-6; author reply 1464-6. No abstract available.

12.
13.

Insights from the gene expression profiling of multiple myeloma.

Claudio JO, Masih-Khan E, Stewart AK.

Curr Hematol Rep. 2004 Jan;3(1):67-73. Review.

PMID:
14695854
14.

Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors.

Wirths O, Waha A, Weggen S, Schirmacher P, Kühne T, Goodyer CG, Albrecht S, Von Schweinitz D, Pietsch T.

Lab Invest. 2003 Mar;83(3):429-34.

PMID:
12649343
15.

Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1.

Lazarevic V, Wahlin A, Hultdin M, Zhan F, Shaughnessy J.

Leuk Lymphoma. 2006 Sep;47(9):1987-8. No abstract available.

PMID:
17065022
16.

Osteopontin dysregulation and lytic bone lesions in multiple myeloma.

Robbiani DF, Colon K, Ely S, Ely S, Chesi M, Bergsagel PL.

Hematol Oncol. 2007 Mar;25(1):16-20.

PMID:
17044113
17.

Mesenchymal stem cell abnormalities in patients with multiple myeloma.

Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, Holy X, Gorin NC, Lopez M, Doucet C, Lataillade JJ.

Leuk Lymphoma. 2007 Oct;48(10):2032-41.

PMID:
17917971
18.

Developmental biology. Making head or tail of Dickkopf.

Nusse R.

Nature. 2001 May 17;411(6835):255-6. No abstract available.

PMID:
11357114
19.

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.

Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, Bonomini S, Hojden M, Sammarelli G, Barillè S, Bataille R, Rizzoli V.

Blood. 2002 Dec 15;100(13):4615-21. Epub 2002 Aug 8.

20.

Zebrafish Dkk1, induced by the pre-MBT Wnt signaling, is secreted from the prechordal plate and patterns the anterior neural plate.

Shinya M, Eschbach C, Clark M, Lehrach H, Furutani-Seiki M.

Mech Dev. 2000 Nov;98(1-2):3-17.

Supplemental Content

Support Center